The concept of pre-COPD: development and feasibility in primary health care

Abstract

BACKGROUND: Chronic obstructive pulmonary disease is often not diagnosed as a preventable disease. The primary physician needs a diagnostic tool to detect chronic obstructive pulmonary disease at an early stage.

AIM: To develop the concept of early detection of chronic obstructive pulmonary disease through a diagnostic tool that stratifies patients according to the risk of disease development.

MATERIALS AND METHODS: Random sample of persons 35–70 years from the lists provided by 15 polyclinics of Saint Petersburg and Arkhangelsk (cross-sectional study, n = 2388). Cohort prospective study (respondents with fixed or variable obstruction, n = 167). All respondents were asked about demographic data, smoking history, risk factors, and the presence of symptoms. Spirometry with a bronchodilator was performed for all participants.

RESULTS: Fixed obstruction was found in 6.8% of the participants in the first phase; obstruction was associated with male sex, smoking status over 10 packs/years, age over 55 years, chronic cough and shortness of breath. Of the 65 members of the cohort with variable obstruction, 23.1% had a fixed obstruction after a year, the risk factors of which were a smoking status of more than 10 packs/years, a night cough and forced expiratory volume in 1 second less than lower limit of normal.

CONCLUSIONS: Based on the results of the two phases of the study, a diagnostic tool was developed for the early detection of chronic obstructive pulmonary disease in the general population by identifying a group of people with preserved lung function and high-risk chronic obstructive pulmonary disease factors.

Keywords

chronic obstructive pulmonary disease / smoking / symptoms / risk factors / spirometry / early detection

References

[1] The Global Strategy for the Diagnosis, Management and Prevention of Chronic obstructive pulmonary disease. Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2023 [Internet]. Available from: https://goldcopd.org/2023-gold-report-2/. Accessed: 23.02.2023.

[2] The Global Strategy for the Diagnosis, Management and Prevention of Chronic obstructive pulmonary disease. Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2023 [Электронный ресурс]. Режим доступа: https://goldcopd.org/2023-gold-report-2/. Дата обращения: 23.02.2023.

[3] Adeloye D, Song P, Zhu Y, et al. NIHR RESPIRE Global Respiratory Health Unit. Global, regional, and national prevalence of, and risk factors for, chronic obstructive pulmonary disease (COPD) in 2019: a systematic review and modelling analysis. Lancet Respir Med. 2022;10(5):447–458. DOI: 10.1016/S2213-2600(21)00511-7

[4] Adeloye D., Song P., Zhu Y. et al. NIHR RESPIRE Global Respiratory Health Unit. Global, regional, and national prevalence of, and risk factors for, chronic obstructive pulmonary disease (COPD) in 2019: a systematic review and modelling analysis // Lancet Respir. Med. 2022. Vol. 10, No. 5. P. 447–458. DOI: 10.1016/S2213-2600(21)00511-7

[5] Klinicheskie rekomendatsii. Khronicheskaya obstruktivnaya bolezn’ legkikh. [Internet]. Available from: https://cr.minzdrav.gov.ru/recomend/603. Accessed: 23.02.2023. (In Russ.).

[6] Клинические рекомендации ХОБЛ 2021 г. [Электронный ресурс]. Режим доступа: https://cr.minzdrav.gov.ru/recomend/603. Дата обращения: 23.02.2023.

[7] US Preventive Services Task Force; Mangione CM, Barry MJ, Nicholson WK, et al. Screening for Chronic Obstructive Pulmonary Disease: US Preventive Services Task Force Reaffirmation Recommendation Statement. JAMA. 2022;327(18):1806–1811. DOI: 10.1001/jama.2022.5692

[8] US Preventive Services Task Force; Mangione C.M., Barry M.J., Nicholson W.K. et al. Screening for Chronic Obstructive Pulmonary Disease: US Preventive Services Task Force Reaffirmation Recommendation Statement // JAMA. 2022. Vol. 327, No. 18. P. 1806–1811. DOI: 10.1001/jama.2022.5692

[9] Agustí A, Celli B. Natural history of COPD: gaps and opportunities. ERJ Open Res. 2017;3(4):00117–2017. DOI: 10.1183/23120541.00117-2017

[10] Agustí A., Celli B. Natural history of COPD: gaps and opportunities // ERJ Open Res. 2017. Vol. 3, No. 4. P. 00117–2017. DOI: 10.1183/23120541.00117-2017

[11] Lowe KE, Regan EA, Anzueto A, et al. COPDGene® 2019: Redefining the diagnosis of chronic obstructive pulmonary disease. Chronic Obstr Pulm Dis. 2019;6(5):384–399. DOI: 10.15326/jcopdf.6.5.2019.0149

[12] Lowe K.E., Regan E.A., Anzueto A. et al. COPDGene® 2019: Redefining the diagnosis of chronic obstructive pulmonary disease // Chronic Obstr. Pulm. Dis. 2019. Vol. 6, No. 5. P. 384–399. DOI: 10.15326/jcopdf.6.5.2019.0149

[13] Han MK, Agusti A, Celli BR, et al. From GOLD 0 to Pre-COPD. Am J Respir Crit Care Med. 2021;203(4):414–423. DOI: 10.1164/rccm.202008-3328PP

[14] Han M.K., Agusti A., Celli B.R. et al. From GOLD 0 to Pre-COPD // Am. J. Respir. Crit. Care Med. 2021. Vol. 203, No. 4. P. 414–423. DOI: 10.1164/rccm.202008-3328PP

[15] Stolz D, Mkorombindo T, Schumann DM, et al. Towards the elimination of chronic obstructive pulmonary disease: a Lancet Commission. Lancet. 2022;400(10356):921–972. DOI: 10.1016/S0140-6736(22)01273-9

[16] Stolz D., Mkorombindo T., Schumann D.M. et al. Towards the elimination of chronic obstructive pulmonary disease: a Lancet Commission // Lancet. 2022. Vol. 400, No. 10356. P. 921–972. DOI: 10.1016/S0140-6736(22)01273-9

[17] Klinicheskie rekomendatsii. Khronicheskii bronkhit (25.08.2021) [Internet]. Available from: https://cr.minzdrav.gov.ru/recomend/655. Accessed: 23.02.2023. (In Russ.)

[18] Клинические рекомендации. Хронический бронхит (25.08.2021) [Электронный ресурс]. Режим доступа: https://cr.minzdrav.gov.ru/ recomend/655. Дата обращения: 23.02.2023.

[19] Andreeva E, Pokhaznikova M, Lebedev A, et al. The RESPECT study: Research on the Prevalence and the diagnosis of COPD and its Tobacco-related etiology: a study protocol. BMC Public Health. 2015;15:831. DOI: 10.1186/s12889-015-2161-z

[20] Andreeva E., Pokhaznikova M., Lebedev A. et al. The RESPECT study: Research on the Prevalence and the diagnosis of COPD and its Tobacco-related etiology: a study protocol // BMC Public Health. 2015. Vol. 15. P. 831. DOI: 10.1186/s12889-015-2161-z

[21] Buhr RG, Barjaktarevic IZ, Quibrera PM, et al. SPIROMICS Investigators. Reversible Airflow Obstruction Predicts Future Chronic Obstructive Pulmonary Disease Development in the SPIROMICS Cohort: An Observational Cohort Study. Am J Respir Crit Care Med. 2022;206(5):554–562. DOI: 10.1164/rccm.202201-0094OC

[22] Buhr R.G., Barjaktarevic I.Z, Quibrera P.M. et al. SPIROMICS Investigators. Reversible Airflow Obstruction Predicts Future Chronic Obstructive Pulmonary Disease Development in the SPIROMICS Cohort: An Observational Cohort Study // Am. J. Respir. Crit. Care Med. 2022. Vol. 206, No. 5. P. 554–562. DOI: 10.1164/rccm.202201-0094OC

[23] Global Lung Function Initiative [Internet]. Available from: https://www.ersnet.org/science-and-research/ongoing-clinical-research-collaborations/ the-global-lung-function-initiative/ Accessed: 24.02.2023.

[24] Global Lung Function Initiative [Электронный ресурс]. Режим доступа: https://www.ersnet.org/science-and-research/ongoing-clinical-research-collaborations/ the-global-lung-function-initiative/ Дата обращения: 24.02.2023.

[25] Pokhaznikova MA, Andreeva EA, Kuznetsova OYu. An experience of performing spirometry by trained general practitioners. Medical alphabet. 2020;(25):34–36. (In Russ.). DOI: 10.33667/2078–5631–2020–25–34–36

[26] Похазникова М.А., Андреева Е.А., Кузнецова О.Ю. Опыт проведения спирометрии врачами общей практики // Медицинский алфавит. 2020. № 25. С. 34–36. DOI: 10.33667/2078–5631–2020–25–34–36

[27] Wan ES, Balte P, Schwartz JE, et al. Association between preserved ratio impaired spirometry and clinical outcomes in US adults. JAMA. 2021;326(22):2287–2298. DOI: 10.1001/jama.2021.20939

[28] Wan E.S., Balte P., Schwartz J.E. et al. association between preserved ratio impaired spirometry and clinical outcomes in US adults // JAMA. 2021. Vol. 326, No. 22. P. 2287–2298. DOI: 10.1001/jama.2021.20939

[29] Yawn BP, Martinez FJ. POINT: Can Screening for COPD Improve Outcomes? Yes. Chest. 2020;157(1):7–9. DOI: 10.1016/j.chest.2019.05.034

[30] Yawn B.P., Martinez F.J. POINT: Can Screening for COPD Improve Outcomes? Yes // Chest. 2020. Vol. 157, No. 1. P. 7–9. DOI: 10.1016/j.chest.2019.05.034

RIGHTS & PERMISSIONS

Eco-Vector